Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Clinical trial NCT03972046 · WITHDRAWN

Trial details

NCT number: NCT03972046
Sponsor: TriHealth Inc.
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma (Skin)Melanoma Stage IIIb-IVM1a Metastasis Skin Tumor Skin BRAF Gene Mutation

Start date: 2019-06-24
Primary completion: 2020-02-03
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.